Skip to main content

Table 1 Demographic, clinical, and tumor characteristics of patients with hepatocellular carcinoma

From: Tissue-infiltrating lymphocytes signature predicts survival in patients with early/intermediate stage hepatocellular carcinoma

Patient demographics Training cohort (n = 352) Validation cohort (n = 393) P value
Age, years
 < 60 274 (77.8%) 290 (73.8%) 0.20
 ≥ 60 78 (22.2%) 103 (26.2%)  
Sex (female), n (%) 60 (17.0%) 53 (13.5%) 0.17
Etiology
 HBV 295 (83.8%) 314 (79.9%) 0.24
 HCV 2 (0.6%) 6 (1.5%)  
 Others 55 (15.6%) 73 18.6%)  
Liver cirrhosis, yes (%) 284 (80.7%) 331 (84.2%) 0.06
AFP, ng/mL 101.5 (6.0, 724.5) 71 (6.0, 865.0) 0.45
Albumin, g/L 4.3 (4.0, 4.6) 4.4 (4.1, 4.7) 0.008
Bilirubin, μmol/L 14.8 (11.5, 18.6) 14.0 (10.6, 18.3) 0.03
ALT, IU/L 41 (27.5, 63.5) 38 (27, 54) 0.06
GGT, U/L 52 (33, 99) 58 (38, 100) 0.11
Tumor number, n (%)
 1 314 (89.2%) 327 (83.2%) 0.06
 2 29 (8.2%) 51 (14.5%)  
 ≥ 3 9 (2.6%) 15 (3.8%)  
Tumor diameter, cm 4.0 (2.5, 7.0) 4.0 (2.5, 6.5) 0.39
Microvascular invasion (yes), n (%) 111 (31.5%) 114 (29.0%) 0.45
Lymphoid metastasis (negative), n (%) 350 (99.4%) 393 (100.0%) 0.13
Tumor differentiation (Edmondson-Steiner grade)
 I-II 266 (75.6%) 284 (72.3%) 0.31
 III-IV 86 (24.4%) 109 (27.7%)  
BCLC
 0 42 (11.9%) 46 (11.7%) 0.52
 A 269 (76.4%) 311 (79.1%)  
 B 41 (11.7%) 36 (9.2%)  
Occlusion, min
 < 15 274 (77.8%) 299 (76.1%) 0.57
 ≥ 15 78 (22.2%) 94 (23.9%)  
  1. Values are presented as no. (%) or median (Q1, Q3)
  2. HBV hepatitis B virus, HCV hepatitis C virus, AFP α-fetoprotein, ALT alanine aminotransferase, GGT γ-glutamyl transferase